Posts

Posted on

Annaly Capital Management, Inc. Announces Redemption of All 18,400,000 Outstanding Shares of 7.50% Series D Cumulative Redeemable Preferred Stock

Annaly Capital Management, Inc. Announces Redemption of All 18,400,000 Outstanding Shares of 7.50% Series D Cumulative Redeemable Preferred Stock

NEW YORK–(BUSINESS WIRE)–
Annaly Capital Management, Inc. (NYSE: NLY), a Maryland corporation (“Annaly” or the “Company”), today provided notice to the record holders (the “Notice of Redemption”) of the Company’s 7.50% Series D Cumulative Redeemable Preferred Stock (the “Series D Preferred Stock”) of the redemption of all 18,400,000 of the issued and outstanding shares of Series D Preferred Stock. The cash redemption amount (the “Redemption Amount”) for each share of Series D Preferred Stock is $25.00 plus accrued and unpaid dividends to, but not including, the redemption date of December 23, 2020 (the “Redemption Date”).

On the Redemption Date, dividends on the Series D Preferred Stock will cease to accumulate and all rights relating to the Series D Preferred Stock will terminate, except the right to receive the Redemption Amount. Payment of the Redemption Amount will be made only upon delivery and surrender of the Series D Preferred Stock to Computershare Inc., the Company’s redemption and paying agent, during its normal business hours at the address specified in the Notice of Redemption.

The Notice of Redemption and related materials were mailed today to holders of record of the Series D Preferred Stock. Questions relating to the Notice of Redemption and related materials should be directed to Computershare Inc. at 1-800-301-5234.

About Annaly

Annaly is a leading diversified capital manager that invests in and finances residential and commercial assets. Annaly’s principal business objective is to generate net income for distribution to its stockholders and to optimize its returns through prudent management of its diversified investment strategies. Annaly is internally managed and has elected to be taxed as a real estate investment trust, or REIT, for federal income tax purposes.

Forward-Looking Statements

This news release and our public documents to which we refer contain or incorporate by reference certain forward-looking statements which are based on various assumptions (some of which are beyond our control) and may be identified by reference to a future period or periods or by the use of forward-looking terminology, such as “may,” “will,” “believe,” “expect,” “anticipate,” “continue,” or similar terms or variations on those terms or the negative of those terms. Actual results could differ materially from those set forth in forward-looking statements due to a variety of factors, including, but not limited to, risks and uncertainties related to the COVID-19 pandemic, including as related to adverse economic conditions on real estate-related assets and financing conditions; changes in interest rates; changes in the yield curve; changes in prepayment rates; the availability of mortgage-backed securities and other securities for purchase; the availability of financing and, if available, the terms of any financing; changes in the market value of our assets; changes in business conditions and the general economy; our ability to grow our commercial real estate business; our ability to grow our residential credit business; our ability to grow our middle market lending business; credit risks related to our investments in credit risk transfer securities, residential mortgage-backed securities and related residential mortgage credit assets, commercial real estate assets and corporate debt; risks related to investments in mortgage servicing rights; our ability to consummate any contemplated investment opportunities; changes in government regulations or policy affecting our business; our ability to maintain our qualification as a REIT for U.S. federal income tax purposes and our ability to maintain our exemption from registration under the Investment Company Act of 1940. For a discussion of the risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. We do not undertake, and specifically disclaim any obligation, to publicly release the result of any revisions which may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements, except as required by law.

Annaly Capital Management, Inc.

Investor Relations

1-888-8Annaly

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: REIT Finance Banking Professional Services Construction & Property

MEDIA:

Logo
Logo
Posted on

Decklar Resources Inc. Announces Amendment to Funding Transaction with San Leon

TORONTO, Nov. 23, 2020 (GLOBE NEWSWIRE) — Decklar Resources Inc. (DKL-TSX Venture) announces that further to its press releases dated August 31, September 30, 2020 and November 2, 2020 regarding the Subscription Agreement entered into with a subsidiary of San Leon Energy Plc, the parties have agreed to an extension until December 14, 2020 in order to finalize certain conditions precedent in the Subscription Agreement, which have taken longer than expected due to travel restrictions in place as a response to Covid-19. All other terms of the transaction remain unchanged.

For further information:

Duncan T. Blount
Chief Executive Officer   Telephone: +1 305 890 6516
Email: [email protected]

David Halpin
Decklar Petroleum   Telephone: +1 403 816 3029
Email: [email protected]

Investor Relations: [email protected]  

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Language

Certain statements made and information contained herein
constitute
“forward-looking information” (within the meaning of applicable Canadian securities legislation). All statements in this news release, other than statements of historical facts, including statements with respect to the Company satisfying all outstanding conditions precedent in order to complete the transaction with San Leon are forward-looking statements. Such statements and information (together, “forward looking statements”) relate to future events or the Company’s future performance, business prospects or opportunities.

All statements other than statements of historical fact may be forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe” and similar expressions) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The Company believes that the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. The Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws. These forward-looking statements involve risks and uncertainties relating to, among other things, changes in oil prices, results of exploration and development activities, uninsured risks, regulatory changes, defects in title, availability of materials and equipment, timeliness of government or other regulatory approvals, actual performance of facilities, availability of financing on reasonable terms, availability of third party
service providers, equipment and processes relative to specifications and expectations and unanticipated environmental impacts on operations. Actual results may differ materially from those expressed or implied by such forward-looking statements.

The Company provides no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not assume the obligation to revise or update these forward-looking statements after the date of this document or to revise them to reflect the occurrence of future unanticipated events, except as may be required under applicable securities laws. 



Posted on

The RMR Group Named a 2020 Top Place to Work by The Boston Globe

The RMR Group Named a 2020 Top Place to Work by The Boston Globe

Alternative Asset Manager Makes Debut on Annual Ranking of Massachusetts Employers

NEWTON, Mass.–(BUSINESS WIRE)–The RMR Group Inc. (Nasdaq: RMR) announced today that is has been named one of The Top Places to Work in Massachusetts in the annual employee-based survey project from The Boston Globe, in the Large Employers category.

The Top Places to Work annually recognizes the most admired workplaces in the state as voted on by employees. Rankings are based on confidential survey information collected from nearly 66,000 individuals at more than 300 Massachusetts organizations. The survey measures employee opinions about their company’s direction, execution, management, work, pay, benefits and engagement. Employers are placed into one of four groups: small, with 99 or fewer employees; midsize, with 100 to 249 workers; large, with 250 to 999; and largest, with 1,000 or more.

Adam Portnoy, President and Chief Executive Officer of RMR, made the following statement:

“We’re proud to be recognized as a Top Place to Work by The Boston Globe and thank our employees for their commitment and support. At our foundation is a talented, entrepreneurial team that has propelled our growth in assets under management from $12 billion to $32 billion over the last decade. As one of the country’s leading alternative asset managers, we are focused on attracting and retaining top talent, building an inclusive culture, and providing a challenging, innovative workplace.”

This recognition follows several recent honors from industry, media and government organizations for RMR and the client companies it manages. In 2020, RMR was recognized by Boston Business Journal as the “Fastest Growing Middle Market Company in Massachusetts,” by Commercial Property Executive as 9th in its list of Top Commercial Property Management Companies and by the U.S. EPA as an “ENERGY STAR Partner of the Year” for the second consecutive year. Last year, RMR achieved the 75th place ranking on Fortune magazine’s 100 Fastest-Growing Companies list for 2019 and also received the Real Estate Management Excellence (REME) Award for Employee & Leadership Development from the Institute of Real Estate Management (IREM).

About The RMR Group Inc.

The RMR Group LLC, or RMR, is a leading U.S. alternative asset management company, unique for its focus on commercial real estate (CRE) and related businesses. It conducts substantially all business for its parent company, The RMR Group Inc. (Nasdaq: RMR). RMR’s vertical integration is strengthened by more than 600 real estate professionals in over 30 offices nationwide who manage $32 billion in assets under management and leverage more than 30 years of institutional experience in buying, selling, financing and operating CRE. RMR benefits from a scalable platform, a deep and experienced management team and a diversity of real estate strategies across its client companies. Recently, RMR has been recognized by The Boston Globe as a “Top Place to Work,” by Fortune magazine as one of the “100 Fastest Growing Companies,” by the Environmental Protection Agency (EPA) as an “ENERGY STAR Partner of the Year,” by Boston Business Journal as the “Fastest Growing Middle Market Company in Massachusetts” and ranked 9th on Commercial Property Executive’s Top Commercial Property Management Companies. RMR is headquartered in Newton, MA and was founded in 1986. For more information, please visit www.rmrgroup.com. Follow RMR on LinkedIn and on Twitter @The_RMR_Group.

Christopher Ranjitkar

Senior Director, Marketing & Corporate Communications

(617) 219-1473

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Banking Other Energy Professional Services Utilities Alternative Energy Energy Other Construction & Property Commercial Building & Real Estate Construction & Property Environment Other Professional Services Human Resources Finance

MEDIA:

Logo
Logo
Posted on

Servus Credit Union donates more than $1 million to deserving community organizations as part of Servus Feel Good Movement™

EDMONTON, Alberta, Nov. 23, 2020 (GLOBE NEWSWIRE) — In May 2020, Servus Credit Union launched the Servus Feel Good Movement. Since it launched, Servus has given away more than a $1 million in donations to deserving community organizations and $100,000 in gifts to individuals, non-profit organizations and businesses as part of their community nomination program.

“We spent a lot of time in the early days of COVID-19 talking to our members and helping them find solutions to some pretty challenging financial situations,” explained Garth Warner, President & CEO of Servus Credit Union. “We knew we wanted to do more to have a positive impact on Albertans and the communities we serve, so it just made sense to find additional impactful ways to help our communities.”

“It’s always our mission to help our members feel good about their money, but we are really proud that we’ve been able to do as much as we have to help improve how Albertans feel overall.”

Supporting the direction of the Servus Feel Good Movement, Servus’s $1 million in donations includes:

  • More than $275,000 to mental health initiatives including the Grande Prairie Friendship Centre and to local branches of the Canadian Mental Health Association including Red Deer, Medicine Hat and Lethbridge.
  • More than $110,000 to food banks throughout the province including Food Banks Alberta.
  • More than $100,000 to family and women support services including Wings of Providence in Edmonton and the Central Alberta Women’s Outreach Society.

In addition to larger scale donations, Servus also gave out $1,000 gifts to 100 deserving Albertans nominated by their friends, peers and colleagues. Some of the nominees include:

More information

Learn more about the Servus Feel Good Movement at servus.ca/feelgoodmovement.

About Servus Credit Union Ltd.

At Servus Credit Union we’re building a better world, one member at a time. We’ve been shaping the financial fitness of Albertans for over 80 years with a full line of secure financial services. We help members manage their money wherever they are through more than 100 branches in 59 communities; online, mobile and telephone banking; and 1900 no-fee ATMs across Canada. We re-invest our profits in our members and the communities we serve. For more information, call 1.877.378.8728 or visit servus.ca.

For more information contact:

Amanda
LeNeve

Manager, Media & Member Engagement
Servus Credit Union
T: 587.920.9158
Email: [email protected]

www.facebook.com/servuscu

www.twitter.com/servuscu



Posted on

Madison Realty Capital Provides $165 Million Loan to Finance 451-Unit Multifamily Development in Boston

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) — Madison Realty Capital, a New York City based real estate private equity firm focused on debt and equity investment strategies, today announced that it successfully originated a $165 million loan to develop a 451-unit, multifamily project located at 1252-1270 Boylston Street in the Boston neighborhood surrounding Fenway Park. The project will be developed by Boston-based Scape North America, a vertically integrated global owner, developer, and operator of multifamily and academic housing, Suffolk Construction will serve as the general contractor and Gensler as the architect.

Ideally located close to the many educational and medical institutions making up Boston’s rapidly growing biotech and life sciences industry, the 291,000-square-foot project will include approximately 20,000 square feet of ground-floor retail space. The state-of-the-art building will offer furnished studio, one- and two-bedroom units well-suited for the growing employment base in the Fenway submarket.

“Boston continues to experience remarkable growth in the areas of life sciences, healthcare, and technology, yet faces an undersupply of residential options for the growing workforce and significant barriers to entry for new residential construction,” said Josh Zegen, Managing Principal and Co-Founder of Madison Realty Capital. “This project will ensure that workers in these sectors as well as the top-tier young professionals graduating from Boston’s leading universities have access to much needed, reasonably priced housing options in the highly sought-after Fenway neighborhood. This $165 million loan at 70% loan-to-cost is emblematic of Madison Realty Capital’s commitment to collaboration and execution amid periods of significant market upheaval.  We look forward to working with this best-in-class team, including Scape North America, Suffolk Construction and Gensler, on an important project in the Boston area.”

“We are excited to partner with Madison Realty Capital on our flagship project in Boston, which will bring attainably-priced housing to the Fenway neighborhood,” said Andrew Flynn, CEO of Scape North America.

This is Madison Reality Capital’s second investment in Boston, following $314 million construction financing provided to Raffles Boston Back Bay Hotel & Residences in July 2019.

About Madison Realty Capital (MRC)

Madison Realty Capital (MRC) is a New York City based real estate private equity firm focused on debt and equity investment strategies with regional offices in key markets including Los Angeles and Dallas. Founded in 2004, MRC has closed on approximately $13 billion of transactions in the multifamily, retail, office, industrial and hotel sectors. The firm manages investments in the United States on behalf of a global investor base. MRC is a fully integrated firm with over 60 employees across all real estate investment, development, and property management disciplines. Among other industry recognitions, MRC has been named to the Commercial Observer’s prestigious “Power 100” list of New York City real estate players and is consistently cited as one of the industry’s top construction lenders.

Media inquiries, contact
Nathaniel Garnick/Grace Cartwright
Gasthalter & Co.
(212) 257-4170
[email protected]



Posted on

VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency

VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the Company’s 3-antigen prophylactic hepatitis B vaccine candidate, seeking approval for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.

“We believe our 3-antigen prophylactic hepatitis B vaccine has the potential to be an important intervention in the fight to eliminate Hepatitis B infections and this MAA submission is a significant milestone for the product and VBI more generally,” said Jeff Baxter, President & CEO. “We are committed to working collaboratively with the EMA throughout the regulatory process to provide access to this vaccine in Europe. As part of the global commercialization strategy for this vaccine, we also remain on track to submit the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the next couple of weeks.”

About Hepatitis B

Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. An estimated 780,000 people die each year from complications of chronic HBV such as liver decompensation and hepatocellular carcinoma.

About VBI’s 3-Antigen Hepatitis B Vaccine

This vaccine is the only 3-antigen hepatitis B vaccine, comprised of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus, and is approved for use and commercially-available in Israel. In December 2017, VBI initiated patient dosing in a global Phase 3 clinical program that consisted of two concurrent pivotal studies: PROTECT, a safety and immunogenicity study, and CONSTANT, a lot-to-lot consistency study. Data from both the PROTECT study and the CONSTANT study, which were announced in June 2019 and January 2020, respectively, comprise the basis for the regulatory submissions in the U.S., Europe, and Canada. This vaccine is sold under the name Sci-B-Vac® in Israel.

To learn more about VBI’s 3-antigen Hepatitis B vaccine visit: https://www.vbivaccines.com/sci-b-vac/

About VBI Vaccines Inc.

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel and recently completed its Phase 3 program in the U.S., Europe, and Canada; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Website Home: http://www.vbivaccines.com/

News and Insights: http://www.vbivaccines.com/wire/

Investors: http://www.vbivaccines.com/investors/

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 5, 2020, and filed with the Canadian security authorities at sedar.com on March 5, 2020, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

VBI

Nicole Anderson

Director, Corporate Communications & IR

Phone: (617) 830-3031 x124

Email: [email protected]

KEYWORDS: Europe United States North America Massachusetts

INDUSTRY KEYWORDS: Research Infectious Diseases FDA Clinical Trials Biotechnology Health Pharmaceutical Science Oncology

MEDIA:

Logo
Logo
Posted on

Chiasma to Participate in Two Investor Conferences in December

NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be presenting and participating in investor meetings at both the Piper Sandler Healthcare Conference as well as the Evercore ISI HealthCONx Conference. Details for each conference are as follows:

Piper Sandler Healthcare Conference:
Date: Monday, November 23, 2020 *
Time: 10:00am ET
Format: Fireside Chat

*
All presentations for the Piper Sandler Healthcare Conference
will be available on Piper
Sandler’s
conference portal at 10
:00
am on Monday, November 23.
Actual dates
for the conference
are November 30 – December 3.

Evercore ISI HealthCONx Conference:
Date: Thursday, December 3, 2020
Time: 1:00pm ET
Format: Panel Discussion, “Easy Pills to Swallow: Oral Drugs for Large Endo Markets” – Chiasma, Crinetics and Lumos

A live audio webcast of each of the two events may be accessed under “Events & Presentations” on the News and Investors section of Chiasma’s website at https://ir.chiasma.com/events-presentations. A replay will be available for 90 days.

About Chiasma
Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. On June 26, 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale in the United States. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company’s website at www.chiasma.com.

Investor Relations and Corporate Communications:

Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
[email protected]

Media Relations:

Patrick Bursey
LifeSci Communications
646-876-4932
[email protected]



Posted on

New Senior Announces Election of Norman K. Jenkins to Board of Directors

New Senior Announces Election of Norman K. Jenkins to Board of Directors

NEW YORK–(BUSINESS WIRE)–
New Senior Investment Group Inc. (“New Senior” or the “Company”) (NYSE: SNR) announced today the election of Norman K. Jenkins, President, Chief Executive Officer and Managing Partner of Capstone Development, LLC, as an independent director to the Company’s Board of Directors (the “Board”), effective immediately.

“On behalf of the Board of Directors of New Senior, we are very pleased to have Norman Jenkins joining us. His deep knowledge of real estate, the hospitality sector, finance, acquisitions and development will give us important perspectives as we work to continue to grow the Company,” said Susan Givens, President & Chief Executive Officer of New Senior. “His public company board expertise and highly relevant industry experience will bring depth to our Board and further our goal of maintaining a board that has the best combination of knowledge, skills, experience and perspectives to provide comprehensive and effective oversight of the Company and support our strategic goals.”

Mr. Jenkins is President and Chief Executive Officer of Capstone Development, LLC, a privately-held developer of institutional-quality lodging assets. Prior to founding Capstone Development in 2009, Mr. Jenkins was with Marriott International for 16 years, serving in various leadership positions before being named Senior Vice President of North American Lodging Development. While with Marriott, Mr. Jenkins was the architect of the company’s industry-leading Diversity Ownership Initiative, which doubled the number of diverse-owned Marriott hotels over a three-year period and resulted in a diverse-owned company becoming Marriott’s second largest franchisee. His experience also includes five years with McDonald’s Corporation holding finance and operating positions.

Mr. Jenkins has served on the Board of Directors of Duke Realty Corporation, a publicly-traded industrial REIT, since 2017. Mr. Jenkins also serves as a director of the Washington DC Developer Roundtable. In addition, Mr. Jenkins is a former member of the Board of Trustees of Suburban Hospital and the Howard University Board of Trustees. Mr. Jenkins earned a BA in Accounting from Howard University, an MBA from George Washington University and is a certified public accountant.

ABOUT NEW SENIOR

New Senior Investment Group Inc. (NYSE: SNR) is a publicly-traded real estate investment trust with a diversified portfolio of senior housing properties located across the United States. New Senior is one of the largest owners of senior housing properties, with 103 properties across 36 states. More information about New Senior can be found at www.newseniorinv.com.

Jane Ryu

646-822-3700

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Finance Consulting Banking Professional Services REIT Residential Building & Real Estate

MEDIA:

Logo
Logo
Posted on

Next-generation Ultrasound System, the SONIMAGE HS2, Delivers Advanced Features for Precision Diagnosis and Interventions

WAYNE, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) — Konica Minolta Healthcare Americas, Inc. introduces the next-generation, compact ultrasound system, SONIMAGE® HS2, featuring advanced image clarity and innovative functionality optimized for point-of-care environments. Building on the company’s advanced ultrasound technology, the HS2 System delivers superior image quality and simplified operation to help clinicians address an array of clinical applications in musculoskeletal, vascular, pain management, interventional and orthobiologics.

“Ultrasound is an invaluable bedside tool that delivers a dynamic evaluation of the anatomy, benefitting the patient and the provider,” says Joan Toth, Senior Product Marketing Manager, Konica Minolta Healthcare. “With the SONIMAGE HS2, clinicians have real-time information to make better decisions sooner, streamline care and enhance patient satisfaction. Clinicians can keep more procedures in-house and expand their services to include more complex interventions safely and efficiently. The SONIMAGE HS2 was designed for ease of use, enabling providers to do more at the point of care quickly and confidently.”

The new SONIMAGE HS2 provides enhanced needle guidance, superior image quality, high-resolution blood flow imaging and an intuitive, wide view touchscreen monitor. Konica Minolta’s Dual Sonic technology utilizes a unique algorithm that transmits two waveforms depending on the focal length, providing the clarity and high signal needed for deep tissue imaging. Improved Tissue Harmonics technology suppresses acoustic noise and increases both frequency and sensitivity for deep tissue and superficial imaging. When coupled with the company’s wide bandwidth L18-4 probe, users achieve exceptional image quality with improved fine details and contrast resolution for precision in diagnostic and interventional procedures.

Additional enhancements include higher resolution and faster frame rates, enabling more clear visualization of small vessels and slow blood flow. Simple Needle Visualization, or SNV®, software is optimized for confident needle guidance.

Simplifying operation is Konica Minolta’s touchscreen display that now includes the ability to annotate and draw lines, notes or figures with a finger and save them for documentation and reporting. Pre-set focused exams minimize the learning curve and facilitate ease-of-use. The touchscreen display can be configured to full screen for ease of viewing, especially during interventions.

Konica Minolta Healthcare is introducing the SONIMAGE HS2 at the virtual annual meeting of the Radiological Society of North America (RSNA), being held November 29 to December 5.

About Konica Minolta Healthcare Americas, Inc.

Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and healthcare information technology. With over 75 years of endless innovation, Konica Minolta is globally recognized as a leader providing cutting-edge technologies and comprehensive support aimed at providing real solutions to meet customer’s needs and helping make better decisions sooner. Konica Minolta Healthcare Americas, Inc., headquartered in Wayne, NJ, is a unit of Konica Minolta, Inc. (TSE:4902). For more information on Konica Minolta Healthcare Americas, Inc., please visit www.konicaminolta.com/medicalusa.

Contact: 
Mary Beth Massat 
Massat Media
224.578.2388
www.konicaminolta.com/medicalusa

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b5fe1fd6-7045-4213-92d0-5cebb238b6cd



Posted on

Agilent Launches New NanoDis System for Nanoparticle Dissolution Testing

Agilent Launches New NanoDis System for Nanoparticle Dissolution Testing

System addresses the pharmaceutical industry’s need for compliant, semi-automated testing of nanoparticle drug formulations.

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced the introduction of the NanoDis System for nanoparticle dissolution testing. Combining Agilent instrumentation and software to enable customers to meet 21 CFR Part 11 and other regulations through its application, the new NanoDis System delivers a dedicated workflow that is automatable and auditable.

Designed in collaboration with Dr. Emre Türeli from nanoparticle manufacturer MyBiotech GmbH, the NanoDis System enables R&D formulation chemists to deliver new formulations into manufacturing faster, and also allows manufacturing teams to deliver consistent batches of QC passed new drug products ready for commercial sale—all in an automated and compliant manner.

“Agilent’s introduction of the NanoDis System is significant in that it is the first nanoparticle testing solution that allows methods to be easily transferred from R&D to QC, supporting scientists in meeting the requirements of United States Pharmacopeia (USP),” said Michael Frank, associate vice president of global marketing for Agilent’s Liquid Phase Separation division. “The NanoDis System can be universally implemented, therefore ensuring that our customers’ global laboratory locations deliver the same results every time. Additionally, the NanoDis System is an end-to-end, single-vendor solution that is fully supported by a dedicated global team.”

Lifesaving drugs are increasingly being developed using nanoparticles for targeted drug delivery. These new dosage forms offer the promise of advancing patient care and treatment outcomes—particularly for oncology and cardiology patients—by reducing side-effects and improving drug solubility and bioavailability. However, nanoparticles can be incredibly difficult to work with from a dissolution testing perspective. This testing is a critical regulatory requirement for the development, manufacturing, and QC of medical drug dosage forms.

“The new NanoDis System gives us a far better insight and thorough understanding of dissolution of nanoparticles, enabling a truly efficient formulation development where we can rely on in-vitro data for the lead formulation selection,” commented Dr. Emre Türeli, CSO MyBiotech GmbH

The Agilent NanoDis System was selected as a finalist for the CPhI Pharma Awards for excellence in Pharma: Analysis, Testing and Quality Control. The awards celebrate the thinkers and creators at the forefront of driving the pharmaceutical industry forward through innovation, technology and strategies.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Media Contact

Catherine Kaye

Agilent Technologies

+44 (0) 7775 410632

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Research Technology Other Technology Clinical Trials Other Health Biotechnology Pharmaceutical Health Science Oncology

MEDIA:

Logo
Logo